within Pharmacolibrary.Drugs.ATC.A;

model A02AB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02AB04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dihydroxialumini sodium carbonate is an antacid used to neutralize stomach acid in the management of conditions such as dyspepsia, peptic ulcer disease, and gastroesophageal reflux disease (GERD). It is usually administered orally and is primarily used for symptomatic relief of hyperacidity. The drug is still approved and in clinical use in some countries.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic parameters are directly reported in published literature for dihydroxialumini sodium carbonate. The drug acts locally in the gastrointestinal tract, and systemic absorption of aluminum or sodium carbonate is minimal under normal conditions.</p><h4>References</h4><ol><li><p>Hussain, MA, et al., &amp; Shefter, E (1987). Phenylpropanolamine pharmacokinetics in dogs after intravenous, oral, and oral controlled-release doses. <i>Biopharmaceutics &amp; drug disposition</i> 8(5) 497–505. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2510080509&quot;>10.1002/bdd.2510080509</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3663885/&quot;>https://pubmed.ncbi.nlm.nih.gov/3663885</a></p></li><li><p>Zhang, J, et al., &amp; Chen, Z (2024). Oral sericin ameliorates type 2 diabetes through passive intestinal and bypass transport into the systemic circulation. <i>Journal of ethnopharmacology</i> 332 118342–None. DOI:<a href=&quot;https://doi.org/10.1016/j.jep.2024.118342&quot;>10.1016/j.jep.2024.118342</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38750984/&quot;>https://pubmed.ncbi.nlm.nih.gov/38750984</a></p></li><li><p>Sandal, N, et al., &amp; Yadav, M (2023). Oral formulation of Prussian blue with improved efficacy for prophylactic use against thallium. <i>Drug development and industrial pharmacy</i> 49(2) 149–158. DOI:<a href=&quot;https://doi.org/10.1080/03639045.2023.2189958&quot;>10.1080/03639045.2023.2189958</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36912805/&quot;>https://pubmed.ncbi.nlm.nih.gov/36912805</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02AB04;
